TEST:

ArteraAI Prostate Test

The ArteraAI MMAI biomarker is prognostic for OS and TTCRPC among patients with omCSPC and may predict for response to MDT. Further work is needed to validate the MMAI biomarker in a broader mCSPC cohort.

"Artera...announced today it has received its California laboratory license from the California Department of Public Health (CDPH). This licensure allows Artera to offer its innovative ArteraAI Prostate Test to one of the largest healthcare markets in the United States."

We successfully applied attention heatmaps and paired spatial proteomics data to interpret the imaging features prognostic of clinical outcomes in localized prostate cancer. Significant correlations were observed between the MMAI image feature attention values and expression of canonical tumor markers (e.g. AR and PSMA) and immune markers (e.g.

We found the prostate biopsy MMAI biomarker, previously shown to be prognostic for distant metastasis and prostate cancer-specific mortality in men getting definitive radiation, to be prognostic for post-RP endpoints: BCR and AP. This biomarker validation study using a real-world cohort further supports the use of MMAI biomarkers in men with PCa outside NA and those treated with RP.

"Artera...will present three abstracts at the 2024 ASCO Annual Meeting demonstrating that its multimodal artificial intelligence (MMAI) platform provides significant prognostic value across various stages of prostate cancer and for early stage breast cancer. These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test...The MMAI platform can provide results to support personalized therapy by combining a patient’s unique clinical data with their pathology slides. Artera is taking a unique approach to this by applying AI to images of hematoxylin and eosin (H&E)-stained pathology slides to provide prognostic and predictive results."

We have shown for the first time that the ArteraAI MMAI biomarker is prognostic for OS in patients with omCSPC. Further, MMAI appears to be predict benefit of MDT with high MMAI demonstrating a greater improvement in MFS following MDT over observation. Further work in validating these findings is warranted to allow for greater personalization in the management of patients with omCSPC.

No abstract available

P=N/A | N=800 | Recruiting | Sponsor: GenesisCare | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023

"ArteraAI...announced today its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance. The test is also the first AI-enabled predictive and prognostic test to be recommended in the guidelines for localized prostate cancer."